Abstract
Pleural diseases are a commonly encountered problem by general physicians and chest specialists alike. Despite this, there has been a lack of research over the last few decades in this important field. This review focuses on new developments in the management of pleural effusions. We have restricted our attention, in the main, to randomised controlled trials. The review is evidence-based with practical suggestions from the authors to practicing clinicians. Specific areas focused on are pleural infection and malignant pleural disease. In pleural infection, the importance of pleural pH is emphasised and we have incorporated the latest evidence on the use of fibrinolytics from the recent multi-centre randomised controlled MIST trial. In malignant pleural effusion, the best way of obtaining closed pleural biopsy is discussed. With regard to pleurodesis, recent data on the importance of knowing your talc particle size is highlighted, as well as the role of fibrinolytics, thoracoscopy and when to use Pleurx catheters. Finally, the latest developments on newer diagnostic markers such as mesothelin in mesothelioma and newer anti-pleural agents such as transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) antagonists have been reviewed.
Keywords: Pleural effusion, malignant pleural disease, pleural infection, new developments
Current Respiratory Medicine Reviews
Title: New Developments in the Management of Pleural Effusions
Volume: 2 Issue: 3
Author(s): Andrew RL Medford and Nick A. Maskell
Affiliation:
Keywords: Pleural effusion, malignant pleural disease, pleural infection, new developments
Abstract: Pleural diseases are a commonly encountered problem by general physicians and chest specialists alike. Despite this, there has been a lack of research over the last few decades in this important field. This review focuses on new developments in the management of pleural effusions. We have restricted our attention, in the main, to randomised controlled trials. The review is evidence-based with practical suggestions from the authors to practicing clinicians. Specific areas focused on are pleural infection and malignant pleural disease. In pleural infection, the importance of pleural pH is emphasised and we have incorporated the latest evidence on the use of fibrinolytics from the recent multi-centre randomised controlled MIST trial. In malignant pleural effusion, the best way of obtaining closed pleural biopsy is discussed. With regard to pleurodesis, recent data on the importance of knowing your talc particle size is highlighted, as well as the role of fibrinolytics, thoracoscopy and when to use Pleurx catheters. Finally, the latest developments on newer diagnostic markers such as mesothelin in mesothelioma and newer anti-pleural agents such as transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) antagonists have been reviewed.
Export Options
About this article
Cite this article as:
RL Medford Andrew and Maskell A. Nick, New Developments in the Management of Pleural Effusions, Current Respiratory Medicine Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339806778018926
DOI https://dx.doi.org/10.2174/157339806778018926 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Immunohistochemical and Serological 90K / Mac-2BP Detection in Hepatocellular Carcinoma Patients: Different Behaviour of Two Monoclonal Antibodies
Medicinal Chemistry Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry How Inhaled Asbestos Causes Scarring and Cancer
Current Respiratory Medicine Reviews Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Lung Cancer: Are we up to the Challenge?
Current Genomics Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry